Novel directions in HIV-1 vaccines revealed from clinical trials

Current Opinion in HIV and AIDS

Volumn 8, Issue 5, 2013, Pages 421-431

  Excler, Jean Louis ^a   Tomaras, Georgia D ^b,c   Russell, Nina D ^d  

^a US Military HIV Research Program (MHRP)   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

clinical trial; correlates; efficacy; HIV 1; vaccine

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY;

AFRICA; ANAPHYLACTOID PURPURA; ANTIBODY RESPONSE; ASIA; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG SAFETY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LEUKOCYTOCLASTIC VASCULITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS TRANSMISSION;

EID: 84883460283     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283632c26     Document Type: Review

References (164)

1. UNAIDS. Report on the Global AIDS Epidemic. UNAIDS; 2012.
2. Kim JH, Rerks-Ngarm S, Excler JL, et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5:428-434.
3. Koff WC. Accelerating HIV vaccine development. Nature 2010; 464:161-162.
4. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619.
5. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med 2008; 359:888-890.
6. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
7. Koff WC. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012; 30:4310-4315.
8. O'Connell RJ, Kim JH, Corey L, et al. Human immunodeficiency virus vaccine trials. In: Bushman FD, Nabel GJ, Swanstrom R, editors. HIV: from biology to prevention and treatment. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2012. pp. 483-504.
9. Kublin JG, Morgan CA, Day TA, et al. HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clin Investig (Lond) 2012; 2:245-254.
10. Launay O, Durier C, Desaint C, et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One 2007; 2:e725.
11. Thiebaut R, Liquet B, Hocini H, et al. A new method for integrated analysis applied to gene expression and cytokines secretion in response to LIPO-5 vaccine in HIV-negative volunteers. Retrovirology 2012; 9 (Suppl 2):P121.
12. Lewis DJ, Fraser CA, Mahmoud AN, et al. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One 2011; 6:e25165.
13. Spearman P, Tomaras G, Montefiori D, et al. Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade C gp140 protein boosting. Retrovirology 2012; 9 (Suppl 2):P137.
14. Ensoli B, Fiorelli V, Ensoli F, et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009; 28:371-378.
15. Bellino S, Francavilla V, Longo O, et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009; 4:195-204.
16. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multiprotein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-518.
17. Leroux-Roels I, Koutsoukos M, Clement F, et al. Strong and persistent CD4\+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 2010; 28:7016-7024.
18. Leroux-Roels G, Maes C, Clement F, et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS One 2013; 8:e55438.
19. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011; 6:e27837.
20. Shao Y, Li T, Liu Y, et al. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in Phase I clinical trial. AIDS Res Hum Retroviruses 2010; 26:A-1-A-184.
21. Vasan S, Schlesinger SJ, Chen Z, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 2010; 5:e8816.
22. Ramanathan VD, Kumar M, Mahalingam J, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009; 25:1107-1116.
23. Currier JR, Ngauy V, de Souza MS, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983.
24. Bart PA, Goodall R, Barber T, et al. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008; 26:3153-3161.
25. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a sixplasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-4092.
26. Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006; 22:678-683.
27. Vasan S, Schlesinger SJ, Huang Y, et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 2010; 5:e8617.
28. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252.
29. Gorse GJ, Baden LR, Wecker M, et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008; 26:215-223.
30. Jin X, Newman MJ, De-Rosa S, et al. A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4\+ T cells in a Phase I clinical trial in HIV-uninfected adults. Vaccine 2009; 27:7080-7086.
31. Wilson CC, Newman MJ, Livingston BD, et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 2008; 15:986-994.
32. Kalams SA, Parker S, Jin X, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231.
33. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649.
34. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-1781.
35. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebocontrolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012; 7:e41936.
36. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240-247.
37. Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26HIV-1 env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013; 207:248-256.
38. Mehendale S, van Lunzen J, Clumeck N, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adenoassociated virus vaccine. AIDS Res Hum Retroviruses 2008; 24:873-880.
39. Mehendale S, Sahay S, Thakar M, et al. Safety and immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Indian J Med Res 2010; 132:168-175.
40. Vardas E, Kaleebu P, Bekker LG, et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adenoassociated virus. AIDS Res Hum Retroviruses 2010; 26:933-942.
41. Wecker M, Gilbert P, Russell N, et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 2012; 19:1651-1660.
42. Fuchs JD, Frank I, Kochar N, et al. First-in-human phase i clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine. Retrovirology 2012; 9 (Suppl 2):P134.
43. Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203:1165-1173.
44. Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-3957.
45. Kennedy JS, Co M,Green S, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008; 26:4420-4424.
46. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8\+ T-cell epitopes. J Virol 2006; 80:4717-4728.
47. Cebere I, Dorrell L, McShane H, et al. Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24:417-425.
48. Peters BS, Jaoko W, Vardas E, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120-2127.
49. Jaoko W, Nakwagala FN, Anzala O, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008; 26:2788-2795.
50. Guimarã es-Walker A, Mackie N, McCormack S, et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA andMVA. HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008; 26:6671-6677.
51. Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008; 198:1482-1490.
52. Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite preexisting vaccinia immunity. Vaccine 2009; 27:4468-4474.
53. Aboud S, Nilsson C, Karlén K, et al. Strong HIV-specific CD4\+ and CD8\+ Tlymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol 2010; 17:1124-1131.
54. Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011; 29:8417-8428.
55. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-619.
56. Gorse GJ, Newman MJ, deCamp A, et al. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol 2012; 19:649-658.
57. Kelleher AD, Puls RL, Bebbington M, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294-297.
58. Hemachandra A, Puls RL, Sirivichayakul S, et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but nonimmunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin 2010; 6:835-840.
59. Harari A, Bart PA, Stohr W, et al. An HIV-1 cladeCDNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63-77.
60. McCormack S, Stö hr W, Barber T, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162-3174.
61. Perreau M, Welles HC, Harari A, et al. DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol 2011; 85:9854-9862.
62. Montefiori DC, Huang Y, Karuna S, et al. rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1. Retrovirology 2012; 9 (Suppl 2):P132.
63. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010; 5:e9015.
64. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172). J Infect Dis 2010; 201:600-607.
65. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5:e12873.
66. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6:e21225.
67. Koblin BA, Casapia M, Morgan C, et al. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One 2011; 6:e24517.
68. Fuchs JD, Morgan C, Bart P, et al. DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies. Retrovirology 2012; 9 (Suppl 2):P136.
69. Mpendo J, Bayingana R, Nanvubya A, et al. Tolerability and acceptability of electroporation during a phase 1 vaccine trial at two sites in Uganda and Rwanda. Retrovirology 2012; 9 (Suppl 2):P126.
70. Borthwick NJ, Ahmed T, Rose A, et al. Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial. Retrovirology 2012; 9 (Suppl 2):P118.
71. Keefer MC, Frey SE, Elizaga M, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948-1958.
72. Walsh SR, Seaman MS, Grandpre LE, et al. Impact of antiorthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine 2012; 31:114-119.
73. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389-1391.
74. Qin L, Gilbert PB, Corey L, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-1312.
75. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-409.
76. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol 2011; 9:889-893.
77. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012; 30:4907-4920.
78. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011; 17:1194-1195.
79. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11 (Suppl A):S127-S137.
80. Tartaglia J, Excler JL, El Habib R, et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3):S291-S298.
81. Paris RM, Kim JH, Robb ML, Michael NL. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010; 9:1055-1069.
82. Zak DE, Aderem A. Overcoming limitations in the systems vaccinology approach: a pathway for accelerated HIV vaccine development. Curr Opin HIV AIDS 2012; 7:58-63.
83. Zak DE, Andersen-Nissen E, Peterson ER, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8\+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 2012; 109:E3503-E3512.
84. Schmidt C, Smith C, Barin B, et al. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother 2012; 8:630-638.
85. Kintu K, Andrew P, Musoke P, et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 2013; 63:1-8.
86. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010; 24:803-809.
87. Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study). J Infect Dis 2012; 206:258-266.
88. Koblin BA, Mayer KH, Noonan E, et al. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012; 60:405-413.
89. Curlin ME, Cassis-Ghavami F, Magaret AS, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a casecontrol study. AIDS 2011; 25:153-158.
90. Cheng C, Wang L, Gall JG, et al. Decreased preexisting Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012; 7:e33969.
91. Van Braeckel E, Koutsoukos M, Bourguignon P, et al. Vaccine-induced HIV seropositivity: a problem on the rise. J Clin Virol 2011; 50:334-337.
92. Silbermann B, Tod M, Desaint C, et al. Short communication: long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retroviruses 2008; 24:1445-1448.
93. Khurana S, Needham J, Park S, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 43:304-312.
94. Cooper CJ, Metch B, Dragavon J, et al. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275-283.
95. Penezina O, Clapham D, Collins J, et al. New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants. Retrovirology 2012; 9 (Suppl 2):P120.
96. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361:1-12.
97. de Souza MS, Ratto-Kim S, Chuenarom W, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188:5166-5176.
98. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206:431-441.
99. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
100. Karasavvas N, Billings E, Rao M, et al. The Thai Phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444-1457.
101. Zolla-Pazner S, Decamp AC, Cardozo T, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013; 8:e53629.
102. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417-420.
103. Gilbert PB, Berger JO, Stablein D, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203:969-975.
104. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a posthoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12:531-537.
105. Paris R, Bejrachandra S, Thongcharoen P, et al. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX B/E. Vaccine 2012; 30:832-836.
106. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX(R) B/E. J Infect Dis 2013; 207:1195-1205.
107. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
108. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366-371.
109. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
110. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-875.
111. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a doubleblind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507-515.
112. Cohen J. More woes for struggling HIV vaccine field. Science 2013; 340:667.
113. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
114. Gilbert P, Wang M, Wrin T, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202:595-605.
115. Forthal DN, Gilbert PB, Landucci G, et al. Recombinant gp120 vaccineinduced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-6603.
116. Forthal DN, Gabriel EE, Wang A, et al. Association of Fcg receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120:2836-2842.
117. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
118. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192:974-983.
119. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-677.
120. Schneider JA, Alam SA, Ackers M, et al. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J Infect Dis 2007; 196:1637-1644.
121. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38:176-186.
122. Liu P, Yates NL, Shen X, et al. Infectious virion capture by HIV-1 gp120 specific IgG from RV144 vaccinees. J Virol 2013; Epub ahead of print.
123. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-1617.
124. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029-7036.
125. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86:11521-11532.
126. Moody MA, Yates NL, Amos JD, et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 2012; 86:7496-7507.
127. Tomaras GD, Ferrari G, Shen X, et al. Vaccine induced plasma IgA specific for the C1-region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013; Epub ahead of print.
128. Nakamura GR, Fonseca DP, O'Rourke SM, et al. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of a4b7 binding. PLoS One 2012; 7:e39045.
129. Gorse GJ, Patel GB, Mandava M, et al. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999; 15:921-930.
130. Banerjee K, Klasse PJ, Sanders RW, et al. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010; 26:445-458.
131. Roussilhon C, Oeuvray C, Mü ller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007; 4:e320.
132. Kam YW, Simarmata D, Chow A, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012; 205:1147-1154.
133. Fitzgerald DW, Janes H, Robertson M, et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 2011; 203:765-772.
134. Li F, Finnefrock AC, Dubey SA, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011; 6:e20479.
135. Koff WC. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012; 30:4310-4315.
136. Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396-407.
137. Haynes BF, Kelsoe G, Harrison SC, et al. B-cell lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423-433.
138. Benjelloun F, Lawrence P, Verrier B, et al. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J Virol 2012; 86:13152-13163.
139. Alam SM, Liao HX, Tomaras GD, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 2013; 87:1554-1568.
140. Liao HX, Tsao CY, Alam SM, et al. Antigenicity and immunogenicity of transmitted/founder, consensus and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 2013; 87:4185-4201.
141. Yates NL, Stacey AR, Nolen TL, et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol 2013; Epub ahead of print.
142. Duerr A. Update on mucosal HIV vaccine vectors. Curr Opin HIV AIDS 2010; 5:397-403.
143. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
144. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
145. Letourneau S, Im EJ, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2:e984.
146. Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122:359-367.
147. Penaloza-MacMaster P, Provine NM, Ra J, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 2013; 87:1373-1384.
148. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored bloodstage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012; 20:2355-2368.
149. Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7:e40385.
150. Excler JL, Parks CL, Ackland J, et al. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010; 38:511-521.
151. Ruzagira E, Wandiembe S, Abaasa A, et al. Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda. PLoS One 2011; 6:e20684.
152. Shaffer DN, Ngetich IK, Bautista CT, et al. HIV-1 incidence rates and risk factors in agricultural workers and dependents in rural Kenya: 36-month follow-up of the Kericho HIV cohort study. J Acquir Immune Defic Syndr 2010; 53:514-521.
153. Price MA, Rida W, Mwangome M, et al. Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr 2012; 59:185-193.
154. Mishra S, Steen R, Gerbase A, et al. Impact of high-risk sex and focused interventions in heterosexual HIV epidemics: a systematic review of mathematical models. PLoS One 2012; 7:e50691.
155. Smith AD, Tapsoba P, Peshu N, et al. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 2009; 374:416-422.
156. Sanders EJ, Okuku HS, Smith AD, et al. High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS 2013; 27:437-446.
157. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012; 380:367-377.
158. van Griensven F, de Lind van Wijngaarden JW. A review of the epidemiology of HIV infection and prevention responses among MSM in Asia. AIDS 2010; 24 (Suppl 3):S30-S40.
159. van Griensven F, Thienkrua W, McNicholl J, et al. Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Bangkok, Thailand. AIDS 2012; Epub ahead of print.
160. Dutta A, Wirtz AL, Baral S, et al. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS 2012; 7:362-368.
161. Nitayaphan S, Ngauy V, O'Connell R, Excler JL. HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Rev Vaccines 2012; 11:805-819.
162. Corey L, Nabel GJ, Dieffenbach C, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011; 3:79ps13.
163. Padian NS, McCoy SI, Manian S, et al. Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr 2011; 58:e23-e28.
164. Cremin I, Alsallaq R, Dybul M, et al. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 2013; 27:447-458.